mcs110
mAbexperimental
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT00757757)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Giant Cell · Phase 2
- Chlamydia · Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 2
- Giant Cell Tumors · Phase 2
- Melanoma · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Stomach Neoplasms · Phase 2
- Synovitis, Pigmented Villonodular · Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
CSF1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- mcs110
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03785496 | Phase 2 | Mar 31, 2019 | Yonsei University |
| NCT03742349 | Phase 1 | Jan 31, 2019 | Novartis |
| NCT03694977 | Phase 2 | Jan 17, 2019 | Seoul National University |
| NCT03285607 | Phase 1 | Sep 30, 2018 | Novartis, Washington University in St. Louis |
| NCT03455764 | Phase 1/Phase 2 (Phase 2) | Jun 22, 2018 | Harvard University, Novartis |
| NCT02807844 | Phase 1/Phase 2 (Phase 2) | Jun 29, 2016 | Novartis |
| NCT02435680 | Phase 2 | Aug 10, 2015 | Novartis |
| NCT01643850 | Phase 2 | Apr 23, 2012 | Novartis |
| NCT00757757 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2008 | Novartis |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 7 | 5 | 2 | 2008 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2019 |
5 organizations
Page 1 / 1